

Claims

1. Use of a GLP-1 agonist for the manufacture of a medicament for lowering total serum lipids.

5

2. Use of a GLP-1 agonist for the manufacture of a medicament for lowering LDL.

3. Use of a GLP-1 agonist for the manufacture of a medicament for lowering small, dense LDL

10

4. Use of a GLP-1 agonist for the manufacture of a medicament for lowering VLDL.

5. Use of a GLP-1 agonist for the manufacture of a medicament for lowering triglycerides.

15 6. Use of a GLP-1 agonist for the manufacture of a medicament for lowering cholesterol.

7. Use of a GLP-1 agonist for the manufacture of a medicament for increasing HDL.

8. Use of a GLP-1 agonist for the manufacture of a medicament for lowering plasma levels of
20 Lp(a) in a human.

9. Use of a GLP-1 agonist for the manufacture of a medicament for inhibiting generation of apo(a) in a human.

25 10. Use of a GLP-1 agonist for the manufacture of a medicament for treating dyslipidemia.

11. The use according to any one of claims 1-10 wherein the GLP-1 agonist binds to a GLP-1 receptor with an affinity constant, K_D , below 1 μM .

30 12. The use according to any one of claims 1-11 wherein the GLP-1 agonist is selected from Arg²⁶, Lys³⁴(N-ε-(γ-Glu(N-α-hexadecanoyl))-GLP-1(7-37), Arg³⁴, Lys²⁶(N-ε-(γ-Glu(N-α-hexadecanoyl))-GLP-1(7-37), exendin-3, exendin-4, Val⁸-GLP-1(7-37), Thr⁸- GLP-1(7-37), Met⁸- GLP-1(7-37), Gly⁸-GLP-1(7-37).

13. A method of lowering total serum lipids, which method comprises administering to a subject an effective amount of a GLP-1 agonist.
14. A method of lowering LDL, which method comprises administering to a subject an effective amount of a GLP-1 agonist.
- 5 15. A method of lowering small, dense LDL, which method comprises administering to a subject an effective amount of a GLP-1 agonist
- 10 16. A method of lowering VLDL, which method comprises administering to a subject an effective amount of a GLP-1 agonist.
- 17 A method of lowering triglycerides, which method comprises administering to a subject an effective amount of a GLP-1 agonist.
- 15 18. A method of lowering cholesterol, which method comprises administering to a subject an effective amount of a GLP-1 agonist.
19. A method of increasing HDL, which method comprises administering to a subject an effective amount of a GLP-1 agonist.
- 20 20. A method of inhibiting generation of apo(a) in vitro or in vivo by administering a GLP-1 agonist.
- 25 21. A method of lowering plasma levels of Lp(a) in a human, comprising administering to said human an effective amount of a GLP-1 agonist.
22. A method of inhibiting generation of apo(a) in a human, comprising administering to said human an effective amount of a GLP-1 agonist.
- 30 23. A method for treating dyslipideamia which method comprises administering to a subject an effective amount of a GLP-1 agonist.
- 24 The method according to any one of claims 13-23 wherein the GLP-1 agonist binds to a
- 35 GLP-1 receptor with an affinity constant, K_D , below 1 μM .

25. The method according to any one of claims 13-23 wherein the GLP-1 agonist is selected from Arg²⁶, Lys³⁴(N-ε-(γ-Glu(N-α-hexadecanoyl))-GLP-1(7-37), Arg³⁴, Lys²⁶(N-ε-(γ-Glu(N-α-hexadecanoyl))-GLP-1(7-37), exendin-3, exendin-4, Val⁸-GLP-1(7-37), Thr⁸- GLP-1(7-37),
5 Met⁸- GLP-1(7-37), Gly⁸-GLP-1(7-37).